What happens if you stop taking Mounjaro?

How effective is Mounjaro for weight loss?

Mounjaro (tirzepatide) is a weekly injection that works on appetite regulation and metabolic pathways. It’s known as a dual agonist because it activates both GLP-1 and GIP receptors. These hormones play a role in hunger, fullness and blood sugar regulation.

In clinical trials, tirzepatide has shown significant weight loss in people living with obesity.

In the SURMOUNT-1 study, people lost up to around 20% of their body weight on average after just over a year of treatment. In a three-year follow-up, weight reduction remained significant in those who continued treatment, and the risk of developing type 2 diabetes was reduced in people with prediabetes. Individual results do vary.

In the head-to-head SURMOUNT-5 study, people with obesity treated with tirzepatide lost around 20% of their body weight on average after 72 weeks, compared with around 14% in the group treated with semaglutide. Side effects were broadly similar and mainly related to the gut.

Despite strong evidence, some people choose to stop treatment. This can be for many reasons. Long-term use is often influenced by how well the medicine is tolerated, personal expectations, access to treatment, cost, and the level of medical and lifestyle support available.

What happens when you stop taking Mounjaro?

It’s common to experience gradual weight regain after stopping Mounjaro.

This isn’t about willpower or doing something “wrong”. When the medication is stopped, the biological systems that regulate hunger, fullness and energy balance are no longer supported in the same way.

Many people notice increased hunger or stronger cravings within a few weeks of stopping. Tirzepatide has a long half-life, so its effects wear off gradually rather than overnight.

Overweight and obesity are chronic conditions. The body often tries to defend its weight through complex biological mechanisms. When weight is lost, processes are triggered that aim to restore previous weight, as the body attempts to return to its earlier energy balance. That can mean stronger hunger signals and weaker feelings of fullness.

Mounjaro helps to dampen these signals. When treatment stops, those counter-regulatory mechanisms can become more noticeable again, increasing the risk of weight regain.

Research shows that weight regain is common after stopping GLP-1 or GLP-1/GIP receptor agonists, although the extent varies between individuals.

The risk of regaining weight depends on several factors, including how long you were on treatment, your lifestyle, your medical background, and the level of follow-up and support you have in place.

Appetite and hunger after Mounjaro (tirzepatide)

Many people describe one of the most noticeable effects of Mounjaro as a calmer appetite. Fullness comes sooner. Portions become naturally smaller. Food noise often quietens down.

These effects happen because tirzepatide activates GLP-1 and GIP receptors, influencing appetite signals in the brain and hormonal pathways that regulate hunger, fullness and blood sugar.

When treatment stops, appetite can change gradually. Hunger signals may return and feel stronger, especially if you’ve become used to feeling full on smaller amounts of food.

Physiological changes after stopping can include increased appetite and stronger cravings for calorie-dense foods, which may lead to weight regain.

You might notice things like:

• more snacking between meals
• larger portion sizes
• feeling full later, or less intensely
• more frequent thoughts about food

These changes aren’t a sign of poor discipline or low motivation. They reflect how your body’s appetite regulation shifts when hormonal support from the medication reduces or stops.

Metabolic changes after stopping GLP-1/GIP-based treatment

Weight isn’t the only thing that can change.

Studies show that improvements in blood sugar control, waist circumference and blood pressure can gradually lessen after GLP-1/GIP-based medicines are stopped, particularly in people who had metabolic challenges before starting treatment.

The degree of change varies from person to person. It depends on factors such as your starting point, how long you were treated, how much weight you lost, and lifestyle factors.

Overall, current evidence suggests that many of the metabolic benefits are linked to ongoing treatment. When medication is withdrawn, there is often a gradual shift back towards previous physiological levels.

Things to consider before stopping Mounjaro

Before deciding to stop Mounjaro, it’s important to weigh up the potential benefits and risks carefully with your doctor.

When treatment ends, the body’s earlier biological mechanisms often become active again. This can increase the risk of weight regain and, for some people, a decline in metabolic balance.

Beyond physical changes, stopping treatment can also affect emotional wellbeing. Many people feel anxious about losing the progress they’ve made, or frustrated if weight starts to increase again. These reactions are common and valid, and they matter.

Stopping treatment is rarely about a lack of motivation. It can relate to concerns about side effects, uncertainty about how long treatment should continue, cost, access, or a feeling that the effect has plateaued.

That’s why open dialogue and follow-up with your doctor are so important before making a decision.

Ongoing medical treatment as support

For many people, continuing medical treatment may be appropriate even after a target weight has been reached.

There’s currently no clear-cut answer to how long maintenance treatment should last. However, studies showing that hunger, weight and metabolic balance often shift back after stopping treatment support the understanding that obesity is a chronic disease, not a failure of character.

When weight is stable, dose adjustments are made in discussion with your doctor, with the aim of finding the lowest effective dose.

Summary

Mounjaro is an effective medical treatment that influences appetite, hunger and metabolism. When treatment stops, the body’s biological mechanisms often reactivate, which commonly leads to increased hunger and gradual weight regain.

Obesity is a chronic disease. For many people, long-term treatment can be part of a sustainable strategy, not a sign of failure.

Once a stable target weight has been reached, medication is adjusted in discussion with your doctor. The goal is to find the lowest effective maintenance dose. This helps keep appetite regulation manageable and reduces hunger and cravings, supporting weight stability over time.

Treatment continues to be combined with lifestyle support and regular follow-up, to create long-term conditions for health and wellbeing.

Sources

European Medicines Agency (EMA). Mounjaro (tirzepatide) product information.
https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf

NEJM. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

The New England Journal of Medicine. Tirzepatide for Obesity Treatment and Diabetes Prevention.
DOI: 10.1056/NEJMoa2410819

The New England Journal of Medicine. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).
https://www.nejm.org/doi/full/10.1056/NEJMoa2416394

JAMA. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4).
https://doi.org/10.1001/jama.2023.24945

JAMA Internal Medicine. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2841273

BMJ. Weight Regain After Cessation of Weight Management Medications: Systematic Review and Meta-Analysis.
https://www.bmj.com/content/392/bmj-2025-085304

eClinicalMedicine. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. 2025.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00614-5/fulltext

‍